Glucosamine + chondroitin
Glucosamine + chondroitin has been studied in 17 papers since 2003: 8 trials and 3 observational studies in people, 1 in animals, 4 reviews. The newest paper, Jun 24, 2025: “The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review”.
17 papers study it28 findingsUpdated
See all 17 papers on glucosamine + chondroitin
At a glance
The findings reach people, from one lab or study. 12 independent labs in 5 countries; 11 trials, none about aging, 3 with no results posted.
“and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09).”
2 of its findings point the other way.
- 12 independent labs in 5 countries
- 2 findings against
- 11 trials, none about aging, 3 with no results posted
- Funders: National Institutes of Health and others
- 1 of 25 findings with company ties
- 4 of 11 trials sponsored by its developers
- Human trial8
- Humans3
- Animals1
Studies in people
See all 8 studies of glucosamine + chondroitin in people8 studies gave glucosamine + chondroitin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on knee osteoarthritis | Randomized trial4 weeks | 24 peopleBothIn knee osteoarthritis patients receiving manual therapy and resistance exercise training | JPMA. The Journal of the Pakistan Medical Association, Jul 1, 2022 |
down: Decreases IL-6-9% (P=0.001, FDR<0.05) | Randomized trial6 months | 96 peopleBothKnee osteoarthritis | Anti-inflammatory & anti-allergy agents in medicinal chemistry, Jan 1, 2020 |
no change: Has no effect on functional impairment | Randomized trial6 months | 164 peopleIn patients with symptomatic knee osteoarthritis | Arthritis & rheumatology (Hoboken, N.J.), Jan 1, 2017 |
| Randomized trial28 days | 20 people10 men; 10 womenaged 20–55 yearsHealthy, overweight, non-smoking adults | PloS one, Feb 26, 2015 | |
down: Decreases joint space narrowingP < 0.0001 | Randomized trial8 months | 80 peopleover 40 yearsMidlife adults; adult patients with Kaschin-Beck disease | Clinical rheumatology, Jan 28, 2010 |
What did studies of glucosamine + chondroitin find?
19Studies of glucosamine + chondroitin measured 19 outcomes, among them inflammation, C-reactive protein and knee pain.
Inflammation
downin humans1
1 study
Inflammation
downin humans1
Glucosamine + chondroitin decreases inflammation in humans.
“With the exception of ubiquitin-mediated proteolysis, and proteins located in the nucleus, all pathways were down-regulated after G&C supplementation.”
Human trial28 daysn = 18
PloS one
Glucosamine + chondroitin decreases inflammation in humans (healthy, overweight) (P = 2.6 x 10-16).
“the most significant being a reduction in the "cytokine activity" pathway (P = 2.6 x 10-16), after glucosamine and chondroitin compared to placebo.”
Human trialhealthy, overweightglucosamine hydrochloride plus chondroitin sulfateplasma1500 mg/d + 1200 mg/d28 daysn = 18
PloS one
C-reactive protein
downin humans1−23%
1 study
C-reactive protein
downin humans1−23%
Glucosamine + chondroitin decreases C-reactive protein in humans (-23%).
“Statistically significantly lower geometric mean CRP concentrations were observed after the G&C intervention compared to placebo (-23%, P = 0.048; ).”
Human trial28 daysn = 18
PloS one
Glucosamine + chondroitin decreases C-reactive protein in humans (healthy, overweight) (-23% (P = 0.048)).
“Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048).”
Human trialhealthy, overweightglucosamine hydrochloride plus chondroitin sulfateserum1500 mg/d + 1200 mg/d28 daysn = 18
PloS one
Knee pain
downin humans1no changein humans1
1 study
Knee pain
downin humans1no changein humans1
Glucosamine + chondroitin decreases knee pain in humans (moderate-to-severe knee pain at baseline) (79.2% vs. 54.3%, P=0.002).
“For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002).”
Human trialmoderate-to-severe knee pain at baseline24 weeksn = 354
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
The New England journal of medicine
Glucosamine + chondroitin showed no clear effect on knee pain in humans (overall) (+6.5 percentage points, P=0.09).
“and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09).”
Human trialoverall24 weeksn = 1,583
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
The New England journal of medicine
Adverse effects
downin humans1
1 study
Adverse effects
downin humans1
Glucosamine + chondroitin decreases adverse effects in humans (osteoarthritis and joint pain) (minimal or no adverse effects).
“most safety studies indicating minimal or no adverse effects.”
Reviewosteoarthritis and joint pain
The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review
Nutrients
Osteoarthritis
downin humans1
1 study
Osteoarthritis
downin humans1
Glucosamine + chondroitin decreases osteoarthritis in humans (osteoarthritis and joint pain) (over 90% of efficacy studies reporting positive outcomes).
“glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.”
Reviewosteoarthritis and joint pain
The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review
Nutrients
Allergic reaction
upin humans1
1 study
Allergic reaction
upin humans1
Glucosamine + chondroitin induces allergic reaction in humans (lumbar degenerative joint disease).
“she developed an itchy rash on her torso and legs. Over the next few hours, the rash spread over her entire body, and facial swelling developed.”
Human triallumbar degenerative joint diseasepillsfemales
Delayed Skin Allergy to Glucosamine Chondroitin Supplement
Cureus
Knee osteoarthritis
no changein humans1
1 study
Knee osteoarthritis
no changein humans1
Glucosamine + chondroitin showed no clear effect on knee osteoarthritis in knee osteoarthritis patients receiving manual therapy and resistance exercise training.
“glucosamine and chondroitin sulfate supplementation for 4 weeks showed no additional benefits.”
Human trialin knee osteoarthritis patients receiving manual therapy and resistance exercise training4 weeksn = 24
JPMA. The Journal of the Pakistan Medical Association
Colorectal serrated polyp
no changein humans1
1 study
Colorectal serrated polyp
no changein humans1
Glucosamine + chondroitin was not clearly linked with colorectal serrated polyp in humans.
“No associations were observed for serrated polyps.”
Humans
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Colorectal adenoma
no changein humans1OR 1
1 study
Colorectal adenoma
no changein humans1OR 1
Glucosamine + chondroitin was not clearly linked with colorectal adenoma in humans (NHS2) (OR = 1.00; 95% CI, 0.86-1.17).
“overall conventional adenoma: OR = 1.00; 95% CI, 0.86-1.17”
HumansNHS2
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
IL-6
downin humans1
1 study
IL-6
downin humans1
Glucosamine + chondroitin decreases IL-6 in humans (knee osteoarthritis) (-9% (P=0.001, FDR<0.05)).
“Serum IL-6 was significantly reduced (by 9%, P=0.001) after GH+CS, and satisfied the FDR<0.05 threshold.”
Human trialknee osteoarthritisserum1500 mg GH + 1200 mg CS daily6 monthsn = 96
Anti-inflammatory & anti-allergy agents in medicinal chemistry
Functional impairment
no changein humans1
1 study
Functional impairment
no changein humans1
Glucosamine + chondroitin showed no clear effect on functional impairment in patients with symptomatic knee osteoarthritis.
“Both placebo treatment and CS/GS combination treatment improved to a similar extent the total WOMAC score as well as the pain and function WOMAC subscale scores”
Human trialin patients with symptomatic knee osteoarthritisCS 1,200 mg plus GS 1,500 mg daily6 monthsn = 164
Arthritis & rheumatology (Hoboken, N.J.)
Joint space narrowing
downin humans1
1 study
Joint space narrowing
downin humans1
Glucosamine + chondroitin decreases joint space narrowing in humans (adult patients with Kaschin-Beck disease) (P < 0.0001).
“Knee joint space of the experimental group narrowed slowly compared to the control group.”
Human trialadult patients with Kaschin-Beck diseaseoral mixtureknee joint1,600 mg twice daily8 monthsn = 80
Effects of chondroitin sulfate and glucosamine in adult patients with Kaschin-Beck disease
Clinical rheumatology
Balance
downin humans1
1 study
Balance
downin humans1
Glucosamine + chondroitin impairs balance in humans (knee osteoarthritis) (approximately a 10% difference).
“balance was better in the placebo group with approximately a 10% difference compared to the GH/CS group.”
Human trialknee osteoarthritis1500/1200mg12 months
Osteoarthritis and cartilage
Mobility
no changein humans1
1 study
Mobility
no changein humans1
Glucosamine + chondroitin showed no clear effect on mobility in humans (knee osteoarthritis).
“There were also no significant differences between the groups in 6-min walk or knee strength”
Human trialknee osteoarthritis1500/1200mg12 months
Osteoarthritis and cartilage
Physical function
no changein humans1
1 study
Physical function
no changein humans1
Glucosamine + chondroitin showed no clear effect on physical function in humans (knee osteoarthritis).
“WOMAC function and pain did not differ significantly between the groups at 6- or 12-month follow-up.”
Human trialknee osteoarthritis1500/1200mg12 months
Osteoarthritis and cartilage
All 19Fewer
What is glucosamine + chondroitin linked with?
6Studies link glucosamine + chondroitin with 6 measures, among them colorectal adenoma, high-risk colorectal adenoma and cardiovascular mortality.
Colorectal adenoma
downin humans1OR 0.9
1 study
Colorectal adenoma
downin humans1OR 0.9
Glucosamine + chondroitin is linked with a lower risk of colorectal adenoma in humans (pooled NHS and HPFS) (10% lower risk (OR = 0.90; 95% CI, 0.81-0.99)).
“10% (OR = 0.90; 95% CI, 0.81-0.99; P heterogeneity = 0.36) lower risk of high-risk adenoma and overall conventional adenoma, respectively”
Humanspooled NHS and HPFS
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
High-risk colorectal adenoma
downin humans1OR 0.74
1 study
High-risk colorectal adenoma
downin humans1OR 0.74
Glucosamine + chondroitin is linked with a lower risk of high-risk colorectal adenoma in humans (pooled NHS and HPFS) (26% lower risk (OR = 0.74; 95% CI, 0.60-0.90)).
“glucosamine + chondroitin use at baseline was associated with a 26% (OR = 0.74; 95% CI, 0.60-0.90; P heterogeneity = 0.23)”
Humanspooled NHS and HPFS
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Cardiovascular mortality
downin humans1HR 0.42
1 study
Cardiovascular mortality
downin humans1HR 0.42
Glucosamine + chondroitin is linked with a lower risk of cardiovascular mortality in humans (HR = 0.42; 95% CI, 0.23-0.75).
“CVD mortality, HR = 0.42; 95% CI, 0.23-0.75”
Humansa year or longern = 16,686
Glucosamine/Chondroitin and Mortality in a US NHANES Cohort
Journal of the American Board of Family Medicine : JABFM
Mortality
downin humans1HR 0.73
1 study
Mortality
downin humans1HR 0.73
Glucosamine + chondroitin is linked with a lower risk of mortality in humans (HR = 0.73; 95% CI, 0.57-0.93).
“Multivariable-adjusted HR showed that the association was maintained after adjustment for age, sex, race, education, smoking status, and physical activity (all-cause mortality, HR = 0.73; 95% CI, 0.57-0.93”
Humansa year or longern = 16,686
Glucosamine/Chondroitin and Mortality in a US NHANES Cohort
Journal of the American Board of Family Medicine : JABFM
Osteoarthritis pain
mixedin humans1
1 study
Osteoarthritis pain
mixedin humans1
Glucosamine + chondroitin is associated with osteoarthritis pain in humans (osteoarthritis).
“The findings of these studies are mixed, owing in some cases to the high rate of placebo response added to by the ethical incorporation of rescue analgesics”
Reviewosteoarthritis
Orthopedics
Colorectal cancer
downin humans1HR 0.55
1 study
Colorectal cancer
downin humans1HR 0.55
Glucosamine + chondroitin is linked with a lower risk of colorectal cancer in humans (use on 4+ days/week for 3+ years) (HR: 0.55; 95 % CI 0.30-1.01).
“Persons reporting use of glucosamine + chondroitin on 4+ days/week for 3+ years had a non-statistically significant 45 % lower CRC risk than non-users (HR: 0.55; 95 % CI 0.30-1.01; p-trend: 0.16).”
Humansuse on 4+ days/week for 3+ years3+ yearsn = 75,137
Use of glucosamine and chondroitin supplements and risk of colorectal cancer
Cancer causes & control : CCC
Has glucosamine + chondroitin been tested in people?
0 of 11 about agingYes: 8 trials and 3 observational studies in people have been published, and 10 trials are registered.
In trials
Phase 4Results posted6 trials
Phase 4Status unknown1 trial
Phase 3Results posted3 trials
Phase 2Results posted1 trial
Phase 2Results posted1 trial
Trial sponsors
Company1 trialPhase 4606 people
Company1 trialPhase 3320 people
Company1 trialPhase 3158 people
Company1 trialPhase 3100 people
Company1 trial114 people
1 trialPhase 4600 people
Ardabil University of Medical Sciences
1 trialPhase 4230 people
US Department of Veterans Affairs
1 trialPhase 31,588 people